A 'remarkable' new twice-yearly injection could halve the rate of cognitive decline in Alzheimer's patients, researchers have discovered.Hailed as a breakthrough in the treatment of the major killer, the jab, named diranersen, doubled the time patients spent in the early stages of the disease.The treatment also reduced levels of tau – a harmful protein linked to brain cell death and one of the hallmarks of Alzheimer's disease – in a first for a drug of its kind. It works differently to the other family of recently-discovered drugs said to help slow Alzheimer's progression, lecanemab and donanemab, which target a different type of brain pathology known as amyloid plaques.While the jab is not a cure, the findings suggest it could become one of the most powerful treatments yet for slowing the progression of the condition.Up to 800,000 people in the UK are thought to be living with Alzheimer's disease, the most common form of dementia – an umbrella term for cruel, brain-robbing diseases.The breakthrough comes as the Daily Mail's Dementia Carers Together Appeal is raising money for new six-week courses for friends and relatives of people living with the disease. A new injection taken just twice a year has halved the rate of cognitive decline in Alzheimer's patients, in a breakthrough scientists have described a 'remarkable' and 'thrilling' The new drug works by switching off the signals that tell brain cells to make tau.Professor Jeffrey Cummings, a co-author of the study, told the Clinical Trials on Alzheimer's Disease conference in Boston: 'We reversed Alzheimer pathology. We removed tau tangles. That's a remarkable statement.' Professor Reisa Sperling, another co-author of the study and a professor of neurology at Harvard Medical School, said the findings were 'thrilling'.Scientists believe Alzheimer's is driven by several harmful processes in the brain. One protein, amyloid, forms sticky plaques around brain cells, while tau builds up inside them, creating damaging tangles. The body's immune system attempts to clear this, but inflammation in the area can worsen the damage.Patients in the UK are already being asked to join upcoming trials of the drug, with recruitment expected to start in spring.Anyone eligible can register their interest through the National Institute for Health and Care Research's Be Part of Research service.Currently, trial locations are set for London, Manchester, Birmingham, Oxford and many more.The new phase two CELIA trial was funded by Biogen, which is developing the drug with Ionis Pharmaceuticals.It enrolled 416 patients with early Alzheimer's disease across multiple centres worldwide.Researchers tested three different doses of the jab against a placebo, with the strongest results found among patients given the lowest dose of 60mg every six months.The drug was injected via lumbar puncture into the spinal fluid in the lower back. After almost two years, those patients had 54 per cent less decline in memory and thinking skills than those in the placebo group. They also showed 38 per cent reduced decline on a measure that included how well patients could manage everyday activities.The researchers also said the drug was largely well tolerated, with side effects including pain at the injection site as well as headaches and confusion, particularly at higher doses. The team also stressed that the new findings must be confirmed in a larger phase-three trial.While diranersen cannot be directly compared with other treatments due to the differences in trials, the findings suggest it may be the best of them all.In separate studies, a drug named lecanemab slowed cognitive decline by 27 per cent, while another, donanemab, reduced decline by 35 per cent. Both drugs were licensed by the UK's medicines regulator, but rejected for routine NHS use by the National Institute for Health and Care Excellence, which said their benefits did not justify the cost to the health service.There are fears that the UK is falling behind in dementia care and treatment.Last week, the Daily Mail revealed that patients risk missing out on timely diagnoses and potentially life-extending treatments because of a shortage of brain scanners. Analysis by Alzheimer's Society found the UK has the lowest number of MRI, CT and PET scanners among 16 comparable developed nations, with existing machines unevenly distributed across the country.The machines are used to diagnose the disease and to check eligibility for cutting-edge treatments that can slow its progression for years. Prime Minister Andy Burnham, whose father Roy died from dementia in September, also said Britain is failing to provide enough support for people diagnosed with the disease and the families caring for them.He promised better pay and career prospects under a National Care Service, which he is working to establish.The Mail's Dementia Carers Together Appeal campaign is being delivered in partnership with Alzheimer's Society and the Mail Force charity.The sessions will give carers vital support and information about their rights and the services available to them.They will allow attendees to meet others in a similar situation and help to address the loneliness, exhaustion and overwhelming responsibilities many face following a loved one's diagnosis. Dementia Carers Together Dementia Carers Together is raising money to fund new courses across the UK to give tens of thousands of struggling unpaid dementia carers vital emotional and practical support. For further information, visit dailymail.com/dementiaHow you can donateOnline: Click here.By Text: To donate £10, text CARER to 70115. To donate £20, text LOVE to 70115. To donate £30, text HEART to 70115. Texts will cost your donation amount plus your network charge.By phone: Call 0300 1234577. Standard charges may apply.By cheque: Send cheques made payable to Mail Force Charity to:Dementia Carers Together, 42 Phoenix Court, Hawkins Road, Colchester CO2 8JY
Major dementia breakthrough as twice-yearly jab halves the rate of cognitive decline making it most powerful treatment yet - here's how YOU could access it
Full Article
Original Source
Read the full article at Dailymail →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.